ClinicalTrials.gg
TerminatedNCT03080935Updated May 29, 2024Results posted

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

A Phase 3 interventional study of Evolocumab in Dyslipidemia, sponsored by Amgen. Terminated at 85 sites in 7 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Why this study was terminated
Amgen business decision to close study early

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing evolocumab in Dyslipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Dyslipidemias.

Enrollment
4th of 10
1,600 · median 409
Started
2017
with 1 other
Phase 3
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
7 of 10
Amgen

Among the 10 studies testing evolocumab in Dyslipidemias, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 7th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 10 studies testing evolocumab in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing evolocumab in Dyslipidemias as a file.
02

Study summary

This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118). Approximately 1600 subjects will be enrolled in this study. This study will continue for 260 weeks (approximately 5 years).

Read the detailed description

This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118). FOURIER is a randomized placebo-controlled study of evolocumab, in patients with clinically evident atherosclerotic CVD on stable effective statin therapy. Subjects at sites participating in FOURIER OLE (Study 20160250) who are eligible and have signed the FOURIER OLE informed consent will be enrolled after completion of FOURIER.

The FOURIER OLE study requires laboratory assessments at day 1, week 12, and thereafter approximately every 6 months from day 1; the corresponding blood samples will be processed using a central laboratory.

Upon enrollment in FOURIER OLE study, subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM) according to their preference. Frequency and corresponding dose of administration can be changed at any scheduled time point where evolocumab is supplied to the subject, provided the appropriate supply is available. It is recommended that subjects continue the same background lipid-lowering therapy (LLT), including statin, as taken during FOURIER.

This study will continue for 260 weeks (approximately 5 years). Subjects ending administration of evolocumab should continue study assessments until the end of study. All subjects will be followed and complete procedures/assessments from enrollment through the date of study termination unless the subject has withdrawn consent, irrespective of whether the subject is continuing to receive treatment.

All deaths and cardiovascular events of interest will be reviewed by an independent external Clinical Events Committee (CEC), using standardized definitions.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study-specific activities/procedures.
  • Subject had completed FOURIER (Study 20110118) while still receiving assigned Product.

Exclusion criteria

Exclusion Criteria:

  • Permanent discontinuation of Product during FOURIER for any reason including an adverse event or serious adverse event.
  • Currently receiving treatment in another investigational device or drug study, or less than 4 weeks since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
  • History or evidence of any other disorder, condition or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Subject has known sensitivity to any of the active substances or (eg, sodium acetate) to be administered during dosing.
  • Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment with evolocumab and for an additional 15 weeks after treatment with evolocumab discontinues.
  • Female subjects of unwilling to use an acceptable method of effective during treatment and for an additional 15 weeks after the last dose of protocol-required therapies.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,600 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Single arm study administering Evolocumab.

    Drug: Evolocumab

Interventions

  • Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.

    Also known as: AMG 145

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event

    All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.

    Time frame: Up to 5 years

Secondary outcomes

  1. Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260

  2. Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260

07

Results

Posted Jan 11, 2023
Limitations and caveats
This study was terminated to coincide with the completion of study 20130295 (NCT02867813). The study was not terminated due to any safety findings.

Participant flow

This was an open-label extension of study 20110118 (NCT01764633). Eligible participants were enrolled after the completion of the 20110118 study. 1600 participants were enrolled at 86 centers in Belgium, Germany, Denmark, France, Italy, Portugal, and Sweden from 13 March 2017 to 04 March 2022.

Participant flow — Overall Study
MilestonePlacebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study
Started745855
Completed695786
Not completed5069
Withdrew: Death3450
Withdrew: Lost to follow-up54
Withdrew: Withdrawal by subject1115

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event

All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event
ParticipantsPlacebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study
Number of Participants Who Experienced an Adverse Event686810
SecondaryPercent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit
Time frame:
Baseline, Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
Reported as:
Mean · Percent Change
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit
Percent ChangePlacebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study
Week 12-66.32 ± 26.88-67.24 ± 25.23
Week 24-66.48 ± 27.52-66.47 ± 28.11
Week 48-62.61 ± 26.60-63.45 ± 26.03
Week 72-65.58 ± 28.13-65.33 ± 28.42
Week 96-64.58 ± 27.01-63.43 ± 28.80
Week 120-64.26 ± 28.31-63.10 ± 29.56
Week 144-66.79 ± 29.22-65.13 ± 31.96
Week 168-65.28 ± 27.55-63.55 ± 29.60
Week 192-65.02 ± 27.93-62.46 ± 26.39
Week 216-64.92 ± 27.93-62.46 ± 28.32
Week 260-66.45 ± 29.84-64.72 ± 29.50
SecondaryPercentage of Participants Who Achieved an LDL-C Level < 40 mg/dL
Time frame:
Baseline, Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL
Percentage of ParticipantsPlacebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study
Baseline in parent study0 (0.0 to 0.5)0 (0.0 to 0.4)
Week 1272.8 (69.4 to 75.9)72.5 (69.4 to 75.4)
Week 2472.9 (69.5 to 76.0)73.4 (70.3 to 76.2)
Week 4866.5 (63.0 to 69.9)68.0 (64.8 to 71.1)
Week 7273.2 (69.8 to 76.3)72.3 (69.1 to 75.2)
Week 9671.1 (67.6 to 74.3)69.2 (65.9 to 72.3)
Week 12070.9 (67.5 to 74.2)68.6 (65.3 to 71.8)
Week 14475.3 (71.2 to 78.9)72.2 (68.5 to 75.7)
Week 16872.3 (68.8 to 75.6)69.3 (65.9 to 72.5)
Week 19271.6 (67.9 to 74.9)66.3 (62.8 to 69.7)
Week 21672.1 (68.6 to 75.4)67.3 (63.9 to 70.6)
Week 26076.1 (71.6 to 80.2)68.8 (64.2 to 73.0)

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo in Parent Study35/745 (4.7%)323/745 (43.4%)451/745 (60.5%)
Evolocumab in Parent Study51/855 (6%)410/854 (48%)528/854 (61.8%)
Most frequent serious events
Showing 10 of 601
Most frequent serious events
EventPlacebo in Parent StudyEvolocumab in Parent Study
Angina pectorisCardiac disorders26/74524/854
Cardiac failureCardiac disorders17/74527/854
Atrial fibrillationCardiac disorders15/74522/854
Acute myocardial infarctionCardiac disorders18/74515/854
PneumoniaInfections and infestations15/74519/854
Angina unstableCardiac disorders15/74513/854
OsteoarthritisMusculoskeletal and connective tissue disorders8/74515/854
Ischaemic strokeNervous system disorders8/74514/854
Peripheral arterial occlusive diseaseVascular disorders12/74512/854
SyncopeNervous system disorders10/74510/854
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo in Parent StudyEvolocumab in Parent Study
HypertensionVascular disorders132/745150/854
NasopharyngitisInfections and infestations75/745111/854
ArthralgiaMusculoskeletal and connective tissue disorders61/74575/854
Back painMusculoskeletal and connective tissue disorders50/74570/854
Diabetes mellitusMetabolism and nutrition disorders60/74557/854
MyalgiaMusculoskeletal and connective tissue disorders55/74547/854
InfluenzaInfections and infestations37/74553/854
Pain in extremityMusculoskeletal and connective tissue disorders24/74550/854
Atrial fibrillationCardiac disorders37/74549/854
CataractEye disorders42/74532/854

Baseline characteristics

The Overall Number of Baseline Participants is made up of all of the participants that received study drug.

Age, Continuous
Age, Continuous(Years)Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyTotal
Mean62.7 ± 9.162.6 ± 8.962.6 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyTotal
Female138151289
Male6077031310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyTotal
Hispanic or Latino172441
Not Hispanic or Latino7288301558
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent StudyTotal
American Indian or Alaska Native000
Asian022
Black or African American101
Native Hawaiian or Other Pacific Islander022
White7067971503
Multiple000
Other385391
08

Study locations

85 sites
  • Algemeen Stedelijk Ziekenhuis Aalst
    Aalst, 9300, Belgium
  • Onze Lieve Vrouw Ziekenhuis Aalst
    Aalst, 9300, Belgium
  • Ziekenhuis Netwerk Antwerpen Middelheim
    Antwerpen, 2020, Belgium
  • Ziekenhuis Netwerk Antwerpen Stuivenberg
    Antwerpen, 2060, Belgium
  • Imelda Ziekenhuis vzw
    Bonheiden, 2820, Belgium
  • Centre Hospitalier Universitaire Brugmann
    Brussels, 1020, Belgium
  • Cliniques universitaires de Bruxelles Hopital Erasme
    Brussels, 1070, Belgium
  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
    Bruxelles, 1200, Belgium
  • Algemeen Ziekenhuis Sint Lucas
    Gent, 9000, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Medif sprl
    Gozee, 6534, Belgium
  • Centre Hospitalier Universitaire de Tivoli
    La Louvière, 7100, Belgium
  • Centres Hospitaliers Jolimont - Hopital de Jolimont
    La Louvière, 7100, Belgium
  • Centre Hospitalier Universitaire de Liege - Sart Tilman
    Liege, 4000, Belgium
  • Centre Hospitalier Regional de la Citadelle
    Liège, 4000, Belgium
  • Algemeen Ziekenhuis Turnhout
    Turnhout, 2300, Belgium
  • Aalborg Hospital
    Aalborg, 9000, Denmark
  • Center for Clinical and Basic Research Aalborg
    Aalborg, 9000, Denmark
  • Aarhus Universitetshospital
    Aarhus N, 8200, Denmark
  • Centre for Clinical and Basic Research Ballerup
    Ballerup, 2750, Denmark
  • Sydvestjysk Sygehus
    Esbjerg, 6700, Denmark
  • Frederiksberg/Bispebjerg Hospitaler
    Frederiksberg, 2000, Denmark
  • Glostrup Hospital
    Glostrup, 2600, Denmark
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Amager Hospital
    Kobenhavn S, 2300, Denmark
  • Odense Universitetssygehus
    Odense, 5000, Denmark
  • Sjaellands Universitetshospital, Roskilde
    Roskilde, 4000, Denmark
  • Svendborg Sygehus
    Svendborg, 5700, Denmark
  • Center for Clinical and Basic Research Vejle
    Vejle, 7100, Denmark
  • Regionshospitalet Viborg
    Viborg, 8800, Denmark
  • Centre Hospitalier Regional Universitaire de Besancon, Hopital Jean Minjoz
    Besancon cedex, 25030, France
  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Trousseau
    Chambray les Tours, 37170, France
  • Hopital Louis Pasteur
    Le Coudray, 28630, France
  • Centre Hospitalier Regional Universitaire de Montpellier - Hopital Arnaud de Villeneuve
    Montpellier cedex 05, 34295, France
  • Centre Hospitalier Universitaire de Nantes - Hopital Guillaume et Rene Laennec
    Nantes Cedex 1, 44093, France
  • Nouvelles Cliniques Nantaises
    Nantes Cedex 2, 44202, France
  • Centre Hospitalier Universitaire de Nice - Hopital Pasteur
    Nice, 06000, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Hopital Pitie-Salpetriere
    Paris, 75013, France
  • Centre Hospitalier de Pau - Hopital Francois Mitterrand
    Pau, 64000, France
  • Centre Hospitalier Universitaire de Reims - Hopital Robert Debre
    Reims, 51100, France
  • Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil
    Toulouse Cedex 9, 31059, France
  • Centre Hospitalier Intercommunal Haute Saone
    Vesoul, 70014, France
  • Universitaets-Herzzentrum Freiburg - Bad Krozingen
    Bad Krozingen, 79189, Germany
  • Klinische Forschung Berlin GbR
    Berlin, 10787, Germany
  • Vivantes Klinikum Neukölln
    Berlin, 12351, Germany
  • Deutsches Rotes Kreuz Kliniken Berlin Köpenick
    Berlin, 12559, Germany
  • Deutsches Herzzentrum Berlin
    Berlin, 13353, Germany
  • Sankt-Johannes-Hospital
    Dortmund, 44137, Germany
  • Gesellschaft fur Wissens und Technologietransfer der Technischen Uni Dresden
    Dresden, 01307, Germany
  • Ambulantes Herzzentrum Kassel
    Kassel, 34121, Germany
  • Universitätsklinikum Köln
    Köln, 50937, Germany
  • Otto von Guericke Universität Magdeburg
    Magdeburg, 39120, Germany
  • Johannes Gutenberg Universität Mainz
    Mainz, 55131, Germany
  • Herz-Gefäß-Zentrum Nymphenburg am Klinikum Dritter Orden
    München, 80333, Germany
  • Deutsches Herzzentrum München des Freistaates Bayern
    München, 80636, Germany
  • Robert Bosch Krankenhaus
    Stuttgart, 70376, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Forschungszentrum Ruhr
    Witten, 58455, Germany
  • Helios Universitätsklinikum Wuppertal
    Wuppertal, 42117, Germany
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Azienda Ospedaliero Universitaria Careggi
    Firenze, 50139, Italy
  • Centro Cardiologico Monzino
    Milano, 20138, Italy
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
    Palermo, 90146, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Azienda Ospedaliera di Perugia Ospedale Santa Maria della Misericordia
    Perugia, 06129, Italy
  • Fondazione Toscana Gabriele Monasterio, Stabilimento Ospedaliero di Pisa
    Pisa, 56124, Italy
  • Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
    Siena, 53100, Italy
  • Hospital Garcia de Orta, EPE
    Almada, 2801-951, Portugal
  • Centro Hospitalar e Universitario de Coimbra EPE
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar Cova da Beira, EPE - Hospital Pero da Covilha
    Covilha, 6200-251, Portugal
  • Hospital Cuf Infante Santo
    Lisboa, 1350-352, Portugal
  • Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Sao Francisco Xavier
    Lisboa, 1449-005, Portugal
  • Centro Hospitalar de Setubal EPE Hospital de Sao Bernardo
    Setubal, 2910-446, Portugal
  • Falu Lasarett
    Falun, 791 82, Sweden
  • Helsingborgs Lasarett
    Helsingborg, 252 47, Sweden
  • Länssjukhuset Ryhov
    Jönköping, 551 85, Sweden
  • Sunderby Sjukhus
    Lulea, 971 80, Sweden
  • Skanes Universitetssjukhus
    Lund, 221 85, Sweden
  • Capio Citykliniken
    Lund, 222 21, Sweden
  • Universitetssjukhuset Ã-rebro
    Orebro, 701 85, Sweden
  • Ostersunds sjukhus
    Ostersund, 831 83, Sweden
  • Akardo MedSite
    Stockholm, 117 27, Sweden
  • Norrlands Universitetssjukhus
    Umea, 901 85, Sweden
09

References and documents

Publications

  • O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29. PubMed 36031810 ↗
  • McClintick DJ, O'Donoghue ML, De Ferrari GM, Ferreira J, Ran X, Im K, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Atar D, Keech A, Giugliano RP, Sabatine MS. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. J Am Coll Cardiol. 2024 Feb 13;83(6):652-664. doi: 10.1016/j.jacc.2023.11.029. PubMed 38325990 ↗
  • Katsiki N, Athyros VG, Mikhailidis DP, Mantzoros C. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism. 2017 Sep;74:43-46. doi: 10.1016/j.metabol.2017.04.007. Epub 2017 Apr 20. No abstract available. PubMed 28477848 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Mar 2022, 59 months.

Results were first posted in Jan 2023, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2017
First posted
Mar 15, 2017
StartActual
Mar 13, 2017
Primary completionActual
Mar 4, 2022
CompletionActual
Mar 4, 2022
Results first posted
Jan 11, 2023
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03080935
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 15, 2017
Start date
Mar 13, 2017
Primary completion
Mar 4, 2022
Completion
Mar 4, 2022
Results posted
Jan 11, 2023
Last update
May 29, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion